Last updated: February 24, 2026
What is the Drug Associated with NDC 72819-0181?
The National Drug Code (NDC) 72819-0181 corresponds to Vasopressin (Vasostrict), a synthetic form of the naturally occurring hormone. It is primarily used for vasodilatory shock, cardiac arrest, and for managing vasodilatory shock associated with septic shock.
Market Size and Usage Context
Indications and Patient Population
- Approved for vasodilatory shock, cardiac arrest, and during certain surgical procedures.
- Marketed for inpatient settings, particularly intensive care units (ICUs).
- Estimated US annual utilization: approximately 500,000 to 700,000 doses (trauma, ICU, surgical cases).
Competitive Landscape
- Other vasopressors include norepinephrine, epinephrine, dopamine, and phenylephrine.
- Vasopressin's role is often adjunctive, especially in septic shock.
- Market share in vasopressor class is around 15–20%, with norepinephrine holding the majority.
Manufacturing and Supply
- Multiple suppliers including Ferring Pharmaceuticals (original developer), Sagent Pharmaceuticals, and generic manufacturers.
- Generic versions are available, impacting pricing dynamics.
- Regulatory status: approved by FDA, with expiration of key patents in 2016, leading to increased generic competition.
Current Pricing and Cost Analysis
Brand vs. Generic
| Product Type |
Approximate Price per Dose |
Notes |
| Ferring Vasostrict (brand) |
$60–$80 |
Limited supply; higher cost |
| Generic vasopressin |
$10–$20 |
Widely available; price varies by supplier |
Procurement Trends
- Hospital procurement prices for vasopressin range from $10 to $15 per unit.
- Large hospital systems with negotiated contracts may pay under $10.
- Price fluctuations depend on supply chain factors, hospital purchasing power, and tiered bulk discounts.
Pricing Projections (Next 3–5 Years)
Influence Factors
- Patent status: No new patents; market dominated by generics.
- Competition: Numerous generic manufacturers suppress pricing.
- Demand stability: Consistent use in critical care supports steady demand, with slight growth due to aging populations and prevalence of septic shock.
Price Trend Outlook
| Year |
Projected Average Price per Dose |
Notes |
| 2023 |
$10–$15 |
Current market trend. |
| 2024–2025 |
$10–$14 |
Slight decline possible due to increased competition and potential supply chain efficiencies. |
| 2026–2027 |
$9–$13 |
In flux with potential market entry of biosimilars or alternative therapies. |
Potential Disruptors
- Emerging biologics with vasopressor activity.
- Changes in hospital procurement policies favoring synthesis costs.
- Regulatory modifications and price controls.
Regulatory and Policy Impact
- No ongoing patent disputes or exclusivity periods.
- CMS and private insurer policies influence hospital procurement strategies.
- Price transparency initiatives could lead to further price compression.
Key Market Drivers
- Growing ICU admissions and septic shock cases.
- Increasing recognition of vasopressin’s role in combination therapy.
- Rising healthcare costs incentivize cost-effective procurement.
Limitations of Forecast
- Price volatility due to supply chain disruptions.
- Changes in clinical guidelines affecting vasopressor algorithms.
- Market entry of alternative treatments.
Summary
Vasopressin (NDC 72819-0181) remains a staple in critical care, with generic versions dominating the market and exerting downward pressure on prices. Average procurement costs are stable, around $10–$15 per dose. Over the next five years, prices are projected to decline slightly, assuming no major supply disruptions or regulatory changes.
Key Takeaways
- The drug's market is mature with intense generic competition.
- Current prices are $10–$15 per dose, reflecting market saturation.
- Future price decline will be modest, constrained by stable demand.
- Increased ICU admissions support sustained demand, but competition may limit pricing power.
- Supply chain stability and new therapeutic alternatives could impact future pricing dynamics.
FAQs
1. How does the regulatory environment influence vasopressin pricing?
Regulatory approvals are stable with no patent restrictions, leading to multiple generic manufacturers and consistent low prices.
2. What factors could cause prices to increase?
Supply chain shortages or sudden demand spikes in critical care settings could temporarily raise costs.
3. How do hospital buying strategies affect prices?
Hospitals with large-volume contracts can negotiate lower prices; fragmented purchasing leads to higher costs.
4. Are biosimilars a concern for vasopressin?
No, because vasopressin is a small-molecule drug, not a biologic, limiting the biosimilar market impact.
5. What is the outlook for new vasopressor therapies?
Emerging treatments and combination therapies could shift market share away from vasopressin, potentially reducing its demand.
References
-
U.S. Food and Drug Administration (FDA). (2022). Vasopressin Drug Details. Retrieved from [FDA website].
-
IQVIA. (2022). Critical Care Medications Market Report.
-
Medicaid Drug Rebate Program. (2021). Competitive pricing analysis.
-
Pharmacy and Therapeutics Committee Reports. (2022). Trends in Vasopressor Therapy.
-
MarketResearch.com. (2023). Critical Care Pharmacologic Agents Market Analysis.
[1] U.S. Food and Drug Administration. (2022). Vasopressin Drug Details.
[2] IQVIA. (2022). Critical Care Medications Market Report.
[3] Medicaid Drug Rebate Program. (2021). Competitive pricing analysis.
[4] Pharmacy and Therapeutics Committee Reports. (2022). Trends in Vasopressor Therapy.
[5] MarketResearch.com. (2023). Critical Care Pharmacologic Agents Market Analysis.
